parkinson, Parkinson's research notebook

Six readers

reader	found	score
genetics Open Targets	no genetic evidence; overall 0.00 from other evidence	0.00
cell type Human Protein Atlas	cell type enhanced, including astrocytes; strongest in retinal bipolar cells	0.75
chemistry Open Targets	reachable by antibody	0.45
trials ClinicalTrials.gov	no Parkinson's trials on record: an open field	1.00
literature PubMed	5 Parkinson's papers of 108	0.76
pathways Reactome	in no curated pathway	0.00

No case: the score is under the bar. Receipt 17088

SORCS2 in dopamine neurons, braak+0.06 (p 0.877) → -0.56 (p 0.115)receipt 17096
SORCS2 in astrocytes, braak-0.87 (p 0.002) → +0.18 (p 0.648)receipt 17095

receipt 17096: SORCS2 in dopamine neurons, braak

power: full sample -0.34 (p 0.173, n 18), 95% CI -0.69 to +0.16. the interval is wide: not enough donors to tell.
confounder: adjusted for sex: -0.32 (p 0.198, n 18). does not hold up.
composition: dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.39 (p 0.109, n 18). could be the mix.
skeptic: leave-one-out range -0.45 to -0.25, sign flips 0; without severely affected donors -0.34 (p 0.173, n 18). fragile.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for SORCS2 in dopamine neurons.

case closed: nothing better to follow up.

receipt 17095: SORCS2 in astrocytes, braak

power: full sample -0.46 (p 0.057, n 18), 95% CI -0.76 to +0.01. the interval is wide: not enough donors to tell.
confounder: adjusted for sex: -0.48 (p 0.042, n 18). holds up.
composition: astrocytes share of nuclei vs axis -0.21 (p 0.413); controlling for it: -0.40 (p 0.103, n 18). could be the mix.
skeptic: leave-one-out range -0.64 to -0.39, sign flips 0; without severely affected donors -0.46 (p 0.057, n 18). robust.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for SORCS2 in astrocytes.

case closed: nothing better to follow up.

loading the receipts